SCHEMBL7110722

SCHEMBL7110722

O=C1Cc2ccccc2Oc2cc(O)cc(O)c21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 0.48
CYP3A4 P08684 4/20 0.48
CYP1A1 P04798 3/20 0.48
CYP1A2 P05177 3/20 0.48
CYP1B1 Q16678 3/20 0.48
CYP2C19 P33261 3/20 0.48
HSD17B10 Q99714 3/20 0.48
MEN1 O00255 2/20 0.48
CYP2C9 P11712 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 2/20 0.48
CYP2D6 P10635 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
PNLIP P16233 1/20 0.46
ALDH1A1 P00352 3/20 0.43
CA12 O43570 2/20 0.43
SLCO2B1 O94956 2/20 0.43
CA4 P22748 2/20 0.43
PSMB5 P28074 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7115723 0.85 ABCG2 (0.53) CYP19A1CYP1A1CYP1A2CYP1B1MAPT
SCHEMBL5112986 0.84 CYP19A1 (0.45) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL14098160 0.84 CYP19A1 (0.45) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL14098129 0.84 CYP19A1 (0.45) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL14098184 0.84 CYP19A1 (0.45) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL7112333 0.82 PLK1 (0.48) CYP3A4HSD17B10MEN1KMT2AMAPT
SCHEMBL7116053 0.81 ALDH1A1 (0.45) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL7115759 0.81 TTR (0.45) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL7112820 0.81 ALDH1A1 (0.40) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
SCHEMBL7113929 0.81 PIK3CA (0.41) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030065021-A1 Tracheal smooth muscle relaxants YAMASHITA SHINYA (JP) 2003-04-03 US disclosed
US-6495592-B1 DIBENZ(B,F)OXEPIN DERIVATIVES; ANTIASTHMATICS NIPPON SUISAN KAISHA, LTD. (JP) 2002-12-17 US disclosed
EP-0805155-B1 NOVEL ANTIOXIDANT TRICYCLIC FUSED HETEROCYCLIC COMPOUND NIPPON SUISAN KAISHA LTD (JP) 2002-03-13 EP disclosed
US-6180659-B1 USING A DIBENZO(B,F)-(OXEPIN OR THIEPIN) COMPOUND NIPPON SUISAN KAISHA, LTD. (JP) 2001-01-30 US disclosed
EP-0885610-A1 TRACHEAL SMOOTH MUSCLE RELAXANT NIPPON SUISAN KAISHA, LTD. (JP) 1998-12-23 EP disclosed
EP-0805155-A1 NOVEL ANTIOXIDANT TRICYCLIC FUSED HETEROCYCLIC COMPOUND NIPPON SUISAN KAISHA, LTD. (JP) 1997-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065021-A1 Tracheal smooth muscle relaxants MYLK, MUSK, CPT1B CYP19A1 3328/4885CYP3A4 2158/4885CYP1A1 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.